Absci Corporation stocks have been trading up by 18.56 percent following positive sentiment around its latest AI-driven biopharma advancements.
Click Here for a Millionaire's POV on Trading ABSI
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Wall Street is lining up behind ABSI, with Leerink, Guggenheim, and BTIG all launching bullish coverage and lifting price targets well above recent trading levels.
- Analysts see ABS-201 from Absci Corporation as a multi‑billion‑dollar opportunity across hair loss and endometriosis, with key proof‑of‑concept data landing in the second half of 2026.
- ABSI ripped roughly 18% on heavy volume after Leerink’s Outperform call and $12 target, turning the name into a momentum trade for active biotech watchers.
- The Jones AI Day panel spotlights Absci’s AI-native drug creation platform and its AI-designed antibodies already in Phase 1 trials, adding visibility but not changing near‑term fundamentals.
- A recent Form 4 shows insider activity in ABSI, giving governance-focused traders another data point, though the brief filing lacks enough detail to read clear direction.
Live Update At 10:03:29 EDT: On Wednesday, June 24, 2026 Absci Corporation stock [NASDAQ: ABSI] is trending up by 18.56%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
ABSI has traded like a biotech rocket lately. Over the last couple of weeks, Absci Corporation climbed from the mid‑$6s to touch above $10 before pulling back to around $8.77. That is a big percentage swing in a short window, and it tells traders one thing: sentiment is in control.
Daily candles show a strong leg up starting 2026/06/04, right after Leerink’s initiation, followed by follow‑through buying and then some profit‑taking. Intraday on the most recent session, ABSI spiked to $10.84 out of the gate, then faded steadily, closing near the low of the day. That pattern — early squeeze, late fade — is classic momentum money locking in gains.
More Breaking News
- POET Technologies Stock Rattled As Class Actions Mount
- PRIM Stock Plunges As Guidance Cut Collides With $2B Backlog Win
- IBM Stock Shows Resilience As AI Partnerships Deepen
- ECX Stock Slides As Traders Eye Weak Balance Sheet
Under the hood, Absci Corporation is still a development‑stage story. Revenue is tiny, about $2.8M, while net income sits near -$29.6M for the latest quarter. Margins are deeply negative and cash burn is real, with free cash flow around -$26.3M. But ABSI also holds a strong current ratio of 6.6 and modest debt, giving it runway to keep funding its AI drug programs. For traders, this is a high‑volatility name tied more to clinical and news catalysts than to traditional earnings power.
Why Traders Are Watching ABSI’s AI Drug Story
ABSI is suddenly on every biotech momentum screen because Wall Street went from curious to outright bullish in just a few weeks. Leerink kicked it off on 2026/06/04, launching coverage of Absci Corporation with an Outperform rating and a $12 price target. They called out ABSI’s AI‑native drug discovery platform and focused on lead asset ABS‑201, now in Phase 1/2 for androgenetic alopecia and advancing into Phase 2 for endometriosis. Leerink went further, suggesting ABSI’s valuation might more than double over the next 18 months if PRLR blockade data come through.
Guggenheim then poured fuel on the fire. On 2026/06/15, it raised its price target on Absci Corporation to $15 from $10 while reiterating a Buy rating. Guggenheim’s deep dive on ABS‑201 landed on more than $5B in potential U.S. sales and over $8B globally, assuming things work. For traders, that sales range explains why ABSI can swing multiple dollars in a day — the upside narrative is massive.
BTIG joined in with a Buy and $9 target, projecting $2.2B in peak sales for ABS‑201 and even comparing the program to a “GLP‑1‑like breakthrough” for hair loss. That kind of language draws momentum traders fast.
The tape confirmed this shift. After Leerink’s call, ABSI ripped about 18% on heavy volume from roughly $7, showing how tightly the stock is tethered to analyst and clinical headlines. Add in the Jones AI Day panel, where Absci Corporation will share the stage with MindWalk and a top AI compute provider, plus an AI‑designed antibody already in Phase 1 trials, and you have a textbook story stock at the intersection of AI and biotech.
Conclusion
For active traders, ABSI now sits in that sweet spot where story, chart, and catalysts all line up. Absci Corporation is burning cash, generating only modest revenue, and showing ugly near‑term profitability metrics. Yet the balance sheet is relatively clean, the current ratio is strong, and Wall Street is suddenly modeling multi‑billion‑dollar sales for ABS‑201 if the science holds up.
The next 12–18 months are the real battleground. Leerink, Guggenheim, and BTIG are all pointing to key proof‑of‑concept and Phase 2 readouts in that window. Positive data would support the bullish price targets in the $9–$15 zone and potentially reset the entire valuation framework for ABSI. Disappointing results, on the other hand, would hit a stock that is already pricing in a lot of hope.
That is why traders need to treat Absci Corporation as a catalyst trade, not a comfortable hold. Size small, plan exits, and watch both the clinical calendar and the tape. As Tim Sykes often says, “Trade the catalyst, not the story — hype fades, price action doesn’t lie.” As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. For ABSI, that means respecting the upside while being ready to cut losses fast if the narrative cracks. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.